Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2012

View Archived Issues

Bayer Yakuhin seeks additional approval for Fosrenol chewable tablets and granules in Japan

Adalimumab evaluated as a treatment for hidradenitis suppurativa in phase II trial

Brimonidine improves erythema in patients with rosacea

Novel IGF-I receptor inhibitors synthesized by Novartis and IRM

Chinese researchers present novel agents for cancer and other disorders

Roche discloses novel antibodies for cancer

Team in Israel patents new genetically modified muscle cells

Researchers at VaxInnate prepare novel dengue vaccines

Ablynx reports promising interim results from phase I/II ALX-0061 study

EYEGUARD-C gevokizumab study enters patient enrollment stage

Xilonix receives FDA fast track designation

Roche divulges new monovalent antigen-binding proteins

ADHD transdermal therapeutic enters phase II study

Shionogi-ViiV Healthcare completes initial registration package for dolutegravir

Combination of belinostat and doxorubicin shows efficacy against soft tissue sarcoma

Sarepta reports promising results from extension study of eteplirsen

Therapy targeting tumor antigens and immune tolerance evaluated in phase I study

VentiRx and Celgene form worldwide collaboration for VTX-2337

Combination therapy proves useful against head and neck cancer

HyperAcute Lung advances to phase IIb/III trial

ITCA-650 evaluated in phase II dose-finding study

EMA determines Sufentanil NanoTab PCA System eligible for centralized review

Tesaro obtains IND clearance to conduct phase I/II study of TSR-011

Pfizer reports topline results from phase III Prevenar 13 trial

OncoMed Pharmaceuticals advances two Notch pathway product candidates

FDA approves Cystaran for corneal cystine crystals

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...